

Tchaikapharma High Quality Medicines Inc.
Interim statement of Financial status
as of 30 of June 2018

	30.06.2018	31.12.2017
	BGN'000	BGN'000
ASSETS		
Non-current assets		
Property, plant and equipment	25 712	26 803
Intangible assets	3 087	2 998
Investment in minority interest	1	1
Trade receivables	5 960	5 960
Total non-current assets	34 760	35 762
Current assets		
Inventories	4 374	5 190
Trade and other receivables	62 785	55 998
Treasury shares redeemed	7	8
Cash and cash equivalents	35	24
Total current assets	67 201	61 220
Total assets	101 961	96 982
LIABILITIES		
Equity		
Share capital	72 200	64 300
Reserves	10 103	9 172
Retained earnings	4 899	8 831
Total	87 202	82 303
Non-current liabilities		
Long-term loans	458	590
Deferred tax liabilities	1 308	1 308
Retirement benefit obligations	83	83
Total non-current liabilities	1 849	1 981
Current liabilities		
Trade and other liabilities	2 456	2 134
Short-term loans	9 778	9 784
Current portion of long-term loans	374	491
Current corporate income tax		78
Other tax liabilities	302	211
Total current liabilities	12 910	12 698
Total liabilities	14 759	14 679
Total equity and liabilities	101 961	96 982

Date of preparation: 27.07.2018

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim statement of comprehensive income
as of 30 of June 2018

	30.06.2018	30.06.2017
	BGN'000	BGN'000
Revenue	18 509	16 514
Other income	10	77
Total income	18 519	16 591
Carrying amount of goods sold	(1 264)	(764)
Changes in inventories of finished products and work in progress	(59)	444
Materials and services	(8 045)	(8 597)
Personnel expenses	(1 807)	(1 628)
Depreciation / amortisation expenses	(1 669)	(1 506)
Other expenses	(132)	(426)
Finance income	6	65
Finance costs	(158)	(179)
Total expenses	(13 128)	(12 591)
Profit before taxation	5 391	4 000
Corporate income tax expense	(492)	(400)
Profit/Loss for the period	4 899	3 600
 Total comprehensive income for the period		
Earnings per share / in BGN per 1 share /	0.07	0.05

Date of preparation: 27.07.2018

Sofia

Prepared by:.....
/ P. Moneva /

Executive Director:.....
/ B. Georgiev /

Tchaikapharma High Quality Medicines Inc.

**Interim cash flow statement
as of 30 of June 2018**

	30.06.2018	30.06.2017
	<i>BGN'000</i>	<i>BGN'000</i>
Cash flows from operating activities		
Proceeds from sale of finished products, goods and services	13 280	15 820
Payments to suppliers of materials, goods and services	(6 635)	(6 766)
Payments to personnel	(1 674)	(1 471)
Payments of interest and dividends		
Corporate income tax payments	(571)	(547)
Other proceeds / payments	(3 252)	(3 324)
<i>Net cash flows</i>	1 148	3 712
Cash flows from investing activities		
Payments on non-current assets acquired	(773)	(1 235)
<i>Net cash flows</i>	(773)	(1 235)
Cash flows from financial activities		
Proceeds from loans	98	97
Payments on loans	(97)	(1 665)
Payment of interest, dividends	(98)	(106)
Payments on finance lease	(269)	(453)
Other proceeds/payments	2	
<i>Net cash flows</i>	(364)	(2 127)
<hr/>		
Change in cash and cash equivalents	11	350
Cash and cash equivalents at the beginning of the period	24	51
Cash and cash equivalents at the end of the period	35	401

Date of preparation: 27.07.2018

Sofia

Prepared by:.....
/ P. Moneva /

Executive

Director:.....

/B. Georgiev /

Tchaikapharma High Quality Medicines Inc.
Interim statement on changes in equity
as of 30 of June 2018

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
Balance as of 01.01.2017	56 600	3 149	4 661	8 585	72 995
Profit/loss for the period				8 831	8 831
Other comprehensive income		477			477
Including from tax effect of the revaluation of property, plant and equipment		(60)			(60)
Total comprehensive income		477		8 831	9 308
Issue of shares by the owners	7 700			(7 700)	
Dividends accrued					
Tantimmes accrued					
Profit transferred to reserves			885	(885)	
Total amount of income and expenses recognised during the period	7 700		885	(8 585)	
Balance as of 31.12.2017	64 300	3 626	5 546	8 831	82 303
Balance as of 01.01.2018	64 300	3 626	5 546	8 831	82 303
Profit/loss for the period				4 899	4 899
Other comprehensive income					
Total comprehensive income				4 899	4 899
Issue of shares by the owners	7 900			(7 900)	
Dividends accrued					
Tantimmes accrued					
Profit transferred to reserves			931	(931)	
Total amount of income and expenses recognised during the period					
Balance as of 30.06.2018	72 200	3 149	6 477	4 899	87 202

Date of preparation: 27.07.2018
Sofia

Prepared by:.....
/P. Moneva/

Executive Director:.....
/B. Georgiev /